BRPI0606281A2 - compostos orgánicos - Google Patents

compostos orgánicos

Info

Publication number
BRPI0606281A2
BRPI0606281A2 BRPI0606281-4A BRPI0606281A BRPI0606281A2 BR PI0606281 A2 BRPI0606281 A2 BR PI0606281A2 BR PI0606281 A BRPI0606281 A BR PI0606281A BR PI0606281 A2 BRPI0606281 A2 BR PI0606281A2
Authority
BR
Brazil
Prior art keywords
kinase
serine
compounds
organic compounds
threonine
Prior art date
Application number
BRPI0606281-4A
Other languages
English (en)
Inventor
Lawrence Blas Perez
Tao Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0606281A2 publication Critical patent/BRPI0606281A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS ORGáNICOS. A presente invenção refere-se a compostos que são úteis para inibir, regular e/ou modular proteínas de tirosina e serina/treonina cinase e semelhantes à cinase, tal como RAF cinase, uma serina/treonina cinase que funciona na trilha de sinalização de MAP cinase. O pedido de patente é também concernido com composições que contêm estes compostos, e métodos de empregá-las para tratar doenças dependentes de tirosina e serina/treonina cinase e semelhantes à cinase, tais como angiogênese, câncer e hipertrofia cardíaca, e com outras matérias objeto.
BRPI0606281-4A 2005-03-17 2006-03-17 compostos orgánicos BRPI0606281A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66288905P 2005-03-17 2005-03-17
PCT/US2006/009713 WO2006102079A1 (en) 2005-03-17 2006-03-17 N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase

Publications (1)

Publication Number Publication Date
BRPI0606281A2 true BRPI0606281A2 (pt) 2009-06-09

Family

ID=36587426

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606281-4A BRPI0606281A2 (pt) 2005-03-17 2006-03-17 compostos orgánicos

Country Status (11)

Country Link
US (1) US20090306107A1 (pt)
EP (1) EP1871773A1 (pt)
JP (1) JP2008533172A (pt)
KR (1) KR20070113295A (pt)
CN (1) CN101175755A (pt)
AU (1) AU2006227447A1 (pt)
BR (1) BRPI0606281A2 (pt)
CA (1) CA2601766A1 (pt)
MX (1) MX2007011435A (pt)
RU (1) RU2007138264A (pt)
WO (1) WO2006102079A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AU2009305669A1 (en) * 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US8889666B2 (en) 2012-02-23 2014-11-18 Taiho Pharmaceutical Co., Ltd. Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
KR20150119401A (ko) 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
TWI603971B (zh) * 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
US10377770B2 (en) * 2015-12-18 2019-08-13 Novartis Ag Tricyclic compounds and compositions as kinase inhibitors
AU2017350440B2 (en) 2016-10-31 2023-01-12 Taiho Pharmaceutical Co., Ltd. Selective inhibitor of exon 20 insertion mutant EGFR
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
FI3677266T3 (fi) 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US12384795B2 (en) 2019-04-24 2025-08-12 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrimido[5,4-b]pyrrolizin compound, optical isomer thereof, preparation method therefor and use thereof
CN114478547B (zh) * 2020-10-23 2026-01-23 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
WO2022083745A1 (zh) * 2020-10-23 2022-04-28 中国科学院上海药物研究所 一种布鲁顿酪氨酸激酶抑制剂的用途
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
CN113651755B (zh) * 2021-07-30 2022-07-29 山东师范大学 一种4-氮杂芴类化合物及其制备方法与应用
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL32503A0 (en) * 1968-08-07 1969-08-27 American Cyanamid Co Pharmaceutical compositions containing pyridinium salts
US4022778A (en) * 1971-11-05 1977-05-10 American Home Products Corporation 10-Aryl-1,2,3,4-tetrahydropyrazino(1,2-α)indole and derivatives thereof
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
JPH11228572A (ja) * 1998-02-20 1999-08-24 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
NZ510588A (en) * 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
BR0116468A (pt) * 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
EP1383771A1 (en) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
DE60215000T2 (de) * 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten

Also Published As

Publication number Publication date
EP1871773A1 (en) 2008-01-02
RU2007138264A (ru) 2009-09-10
AU2006227447A1 (en) 2006-09-28
JP2008533172A (ja) 2008-08-21
CA2601766A1 (en) 2006-09-28
US20090306107A1 (en) 2009-12-10
WO2006102079A1 (en) 2006-09-28
MX2007011435A (es) 2007-12-05
KR20070113295A (ko) 2007-11-28
CN101175755A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CO6382129A2 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
ECSP14026271A (es) Compuestos de indol e indazol que activan la ampk
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
BRPI0412488A (pt) derivados de heteroarila e arila trissubstituìdas poro moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a este
BR112012032028A2 (pt) compostos de tioacetato, composições e métodos de uso.
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
BR112012004335A8 (pt) Composto, composição farmacêutica, e, uso do composto.
GEP20156251B (en) Compounds and methods for kinase modulation, and indications therefor
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
CO6602158A2 (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
BR112015028017A2 (pt) composto, composição farmacêutica, e, uso de um composto
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112012000968A8 (pt) Composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
MA32400B1 (fr) Isoquinoléines et isoquinolinones substituées en tant qu'inhibiteurs de rho-kinase
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BRPI0517737A (pt) inibidores de quinase
JOP20220355A1 (ar) مثبطات rip1k

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.